Industry Overview:
The global animal model market was valued at USD 0.82 billion in 2024 and is estimated to reach USD 2.25 billion in 2035, reflecting a growth rate of 9.6%. The animal model market is propelled by surging pharmaceutical R&D investments amid rising chronic disease prevalence, making preclinical testing indispensable for drug efficacy and safety validation, while advancements in genetic engineering like CRISPR enable precise disease-mimicking models that boost translational research accuracy. Regulatory mandates from FDA and EMA require rigorous animal-based preclinical data before human trials, and expanding biotech sectors alongside personalized medicine demands drive adoption of specialized transgenic models. Growing academic and CRO collaborations further accelerate demand for reliable, reproducible animal systems.
Industry Insights: Scale, Segments, and Shifts
• Market Size & Growth: The global animal model market is projected to reach USD 2.55 billion by 2035, registering a CAGR of 9.6% between 2025 and 2035.
• Segment Analysis: Mice models accounted for approximately 65% of the global animal model market by species, holding dominant position due to their genetic similarity to humans, short breeding cycles, and versatility in oncology and immunology research.
• Regional Highlights: Mice models accounted for approximately 65% of the global animal model market by species, holding dominant position due to their genetic similarity to humans, short breeding cycles, and versatility in oncology and immunology research.
• Competitive Landscape: Major players like Charles River Laboratories and The Jackson Laboratory lead through vertically integrated breeding, CRISPR innovations, and global facilities, as Taconic Biosciences and genOway specialize in humanized and PDX models for oncology, with Inotiv and Crown Bioscience focusing on custom services and immuno-oncology. Strategic acquisitions, such as Charles River’s Vigene Biosciences buyout, deepen viral-vector capabilities, and competition intensifies via partnerships with pharma for precision models.
Factors Shaping the Next Decade
• Market Gaps / Restraints: High costs of genetically engineered models, 60-80% pricier than conventional ones, hinder adoption in budget-limited settings, ethical concerns and strict welfare regulations demand facility upgrades and delay timelines, and emerging alternatives like organoids and 3D cultures challenge traditional reliance.
• Key Trends and Innovations: Shift to humanized and CRISPR-edited models improves predictive accuracy by 40% in drug testing, integration of AI phenotyping and microbiome-defined strains enhances reproducibility, and rise of PDX for oncology mimics tumor microenvironments effectively.
• Potential Opportunities: Personalized medicine fuels demand for mutation-specific models amid aging populations, emerging markets like Brazil offer growth via biotech investments, and partnerships for bioengineered organs expand therapeutic applications.
Recent Development:
In September 2025, A new product called Amino Collagen NMN was released by Meiji Co. Ltd. to improve its enhanced supplement goods worldwide. It contains animal model with nicotinamide mononucleotide (NMN).
Industry Outlook Scope:
By Animal Type
• Mice
• Rats
• Fish
• Birds
• Cattle
• Other Animals
By Service
• Breeding
• Cryopreservation
• Rederivation & Quarantine
• Genetic Testing
• Other Services
By Application
• Oncology
• Cardiovascular & Metabolic Disorders
• Neurology & Psychiatry
• Immunology & Infectious Diseases
• Toxicology & Safety Assessment
• Others
By End-User
• Pharmaceutical & Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Other End-Users
Geographical Insights: Emerging Corridors of Growth
• Regional Overview: North America dominates at 47-50% share, driven by US R&D infrastructure and 17-22 million annual research animals mostly mice/rats, while Europe benefits from EMA frameworks ensuring ethical reproducible models with UK/Germany hubs advancing transgenics. Asia-Pacific surges via China’s preclinical hubs and affordable outsourcing as Japan focuses on aging research, Latin America led by Brazil grows through pharma manufacturing while MEA lags but eyes biomed funding, and global shift favors genetic models amid precision medicine boom.
• Countries to Watch: USA leads with 7.5% CAGR through NIH and biotech expansion, Brazil follows at 7.0% via manufacturing initiatives, Japan at 6.5% targets precision meds for aging, and Germany at 6.4% leverages pharma strength. .
Download Free Regional Sample Report
Regulatory Environment and Policy Support
• Government Regulations & Supportive Policies: FDA/EMA mandate animal preclinical data for trial approvals enforcing welfare via IACUC oversight, EU Directive 2010/63/EU standardizes 3Rs (replace, reduce, refine), NIH funds boost US model development with similar support in Japan/China, and policies promote ethical breeding and alternatives integration.
• Key Government Initiatives: NIH allocates billions for preclinical research prioritizing genetic models, China’s biomed programs subsidize domestic breeding facilities, Brazil’s biotech policies fund pharma R&D infrastructure, and EU Horizon funds translational animal studies.
Competitive Landscape and Strategic Outlook
Leaders in the animal model market are aggressively expanding through mergers and acquisitions alongside cutting-edge CRISPR technologies tailored for oncology and immunology applications, while a strategic focus shifts toward establishing advanced facilities in Asia coupled with AI-integrated phenotyping to enhance model precision and data analytics. Pharma partnerships are increasingly securing long-term contracts to ensure stable revenue streams for model developers, and the competitive outlook strongly favors innovators who specialize in humanized strains offering superior translational value in drug discovery. Amid a projected 6-9% CAGR, companies prioritizing scalability and ethical compliance will capture greater market share, with overall dynamics rewarding agility in adopting hybrid technologies and pursuing regional diversification.
Industry Competition:
• Charles River Laboratories
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• genOway
• Inotiv
• Crown Bioscience
• Janvier Labs
• Harbour BioMed
• BIOCYTOGEN
• Envigo
• Labcorp Drug Development
• Shanghai Model Organisms Center
Analyst Perspective
Market sustains 6-8.7% CAGR to 2035 balancing innovation with ethics, mice/cancer dominance persists but alternatives pressure costs, US/Asia growth outpaces Europe while regulatory shifts bear watching. Geopolitical supply chains favor localized breeding, and long-term hybrid models blending animals with in vitro gain traction.
What to Expect from Outlook:
1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global Animal model Market
2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global Animal model Market sector.
3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.
4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Animal model Market with a forecast for the decade by both market share (%) & revenue (USD Billion).
1. Key
Findings
2. Introduction
2.1. Executive Summary
2.2. Regional Snapshot
2.3. Market Scope
2.4. Market Definition
3. Across
The Globe
3.1. Factors Affecting End Use Industries
3.2. Upcoming Opportunities
3.3. Market Dynamics
3.3.1. Ongoing Market Trends
3.3.2. Growth Driving Factors
3.3.3. Restraining Factors
3.4. Value Chain Analysis
3.5. PORTER’s & PESTLE Analysis
3.6. Key Developments
3.7. Key Industry Patents
3.8. Pricing Analysis
4. Global
Animal model Market Overview, By Animal Type
4.1. Market Size (US$ Mn) Analysis, 2019 –
2034
4.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
4.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
4.3.1. Mice
4.3.2. Rats
5. Global
Animal model Market Overview, By Application
5.1. Market Size (US$ Mn) Analysis, 2019 – 2034
5.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
5.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
5.3.1. Cancer
5.3.2. Immunological Disease
6. Global
Animal model Market Overview, By Region
6.1. Market Size (US$ Mn) Analysis, 2019 –
2034
6.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
6.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Middle East & Africa
6.3.5. South America
7. North
America Animal model Market Overview
7.1. Market Size (US$ Mn) Analysis, 2019 –
2034
7.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
7.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
7.3.1. By Country
7.3.1.1. U.S.
7.3.1.2. Canada
7.3.1.3. Mexico
7.3.2. By Animal Type
7.3.3. By Application
8. Europe
Animal model Market Overview
8.1. Market Size (US$ Mn) Analysis, 2019 –
2034
8.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
8.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
8.3.1. By Country
8.3.1.1. UK
8.3.1.2. Italy
8.3.1.3. Spain
8.3.1.4. Germany
8.3.1.5. France
8.3.1.6. Rest of Europe
8.3.2. By Animal Type
8.3.3. By Application
9. Asia
Pacific Animal model Market Overview
9.1. Market Size (US$ Mn) Analysis, 2019 –
2034
9.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
9.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
9.3.1. By Country
9.3.1.1. China
9.3.1.2. Japan
9.3.1.3. India
9.3.1.4. South Korea
9.3.1.5. Rest of Asia Pacific
9.3.2. By Animal Type
9.3.3. By Application
10. Middle East & Africa Animal model Market Overview
10.1. Market Size (US$ Mn) Analysis, 2019 – 2034
10.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
10.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
10.3.1. By Country
10.3.1.1. GCC
10.3.1.2. South Africa
10.3.1.3. Rest of Middle East & Africa
10.3.2. By Animal Type
10.3.3. By Application
11. South America Animal model Market Overview
11.1. Market Size (US$ Mn) Analysis, 2019 – 2034
11.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
11.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Argentina
11.3.1.3. Rest of South America
11.3.2. By Animal Type
11.3.3. By Application
12. Country Wise Market Analysis
12.1. Growth Comparison By Key Countries
13. Competitive Landscape
13.1. Market Share (%) Analysis, By Top Players
13.2. Maret Structure Analysis, By Tier I &
II Companies
14. Company Profiles
14.1. Charles River Laboratories
14.1.1. Company Overview
14.1.2. Business Segments
14.1.3. Financial Insights
14.1.4. Key Business Aspects (Noise Analysis)
14.2. The Jackson Laboratory
14.3. Taconic Biosciences, Inc.
14.4. genOway
14.5. Inotiv
14.6. Crown Bioscience
14.7. Janvier Labs
14.8. Harbour BioMed
14.9. BIOCYTOGEN
14.10. Envigo
14.11. Labcorp Drug Development
14.12. Shanghai Model Organisms Center
15. Analysis & Recommendations
15.1. Targeting Segment
15.2. Targeting Region
15.3. Market Approach
16. Research Methodology
17. Disclaimer
